Understanding how prostate cancer changes and becomes resistant to treatment
Official title: Molecular mechanisms underlying lineage plasticity in prostate cancer
Funded at Dana-Farber Cancer Inst · NIH-10976686 · Data updated 2026-11-12
This study is looking at how prostate cancer can change and become tougher to treat, so we can find new ways to help patients with advanced prostate cancer.
Quick facts
| Grant type | R37 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | April 1, 2025 |
| Project end | March 31, 2027 |
| Funding year | 2025 |
| Award (this year) | $601,022 |
| NIH project number | 4R37CA241486-06 |
| Project ID | NIH-10976686 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with advanced prostate cancer who are experiencing resistance to androgen receptor-targeted therapies.
✕Less likely to help
Patients with early-stage prostate cancer who have not yet undergone treatment may not benefit from this research.
What this research studies
This research investigates the mechanisms by which prostate cancer can change its characteristics and become resistant to therapies that target the androgen receptor. It focuses on how tumors can lose their typical prostate identity and adopt new traits that make them harder to treat. By analyzing patient data and laboratory models, the research aims to identify specific genes and pathways involved in this process, which could lead to new treatment strategies for patients with advanced prostate cancer.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with androgen-resistant prostate cancer.
How similar studies have gone: Other research has shown promise in understanding lineage plasticity in cancer, suggesting that this approach could lead to significant advancements in treatment.
Where this research is happening
-
Dana-Farber Cancer Inst
Boston, United States Active
Researchers
- Principal investigator: Beltran, Himisha — Dana-Farber Cancer Inst
- Study coordinator: Beltran, Himisha
Related research
Other NIH-funded projects on the same topics.
-
Cardiovascular risk planning and reduction for men with prostate cancer
A program to better predict and reduce heart disease risk in men treated for prostate cancer, especially older patients.
-
Effects of ADT on motivation and emotion in prostate cancer patients
This project looks at how androgen deprivation therapy may affect motivation and mood over time in men with prostate cancer.
-
Causal Protein Markers to Understand and Predict Prostate Cancer Risk in Africans and Europeans
A cancer research project looking at proteins linked to prostate cancer to better understand why it happens and how risk differs between African and European populations.
-
Ethical multimodal AI platform to improve prostate cancer detection with ultrasound
A patient-friendly AI system uses ultrasound and MRI information to help doctors better find prostate cancer, aiming to improve accuracy and access.
-
Characterizing epigenetic targets in prostate cancer to help AR-driven cancer
A research project at MD Anderson aims to understand how epigenetic factors shape androgen receptor signaling in prostate cancer to find new ways to treat resistant forms of the disease.
-
AR and RNA-binding in prostate cancer resistance
A cancer research grant exploring how the androgen receptor’s interaction with RNA may drive treatment resistance in prostate cancer, with potential to guide new therapies.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.